Mestinon (Pyridostigmine Bromide)

Pyridostigmine bromide blocks the enzyme acetylcholinesterase, which normally breaks down acetylcholine at nerve‑muscle junctions. By inhibiting this enzyme, the drug raises acetylcholine levels, enhancing stimulation of muscle receptors and improving muscle contraction and gastrointestinal motility.

The exact dose of Mestinon is individualized by the prescribing clinician based on the patient’s condition, severity, age, renal function and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for pyridostigmine bromide in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Mestinon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mestinon belongs to the acetylcholinesterase inhibitor class, which directly increases acetylcholine at the neuromuscular junction. Unlike agents that act centrally or via calcium channel blockade, pyridostigmine provides a peripheral mechanism, making it especially effective for myasthenia gravis and postoperative ileus, while having a distinct side‑effect profile.

Mestinon tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Mestinon is taken orally, usually with a glass of water. The tablet can be taken with or without food, but consistent timing with meals may help reduce gastrointestinal discomfort. Patients should swallow the tablet whole and not crush or chew it unless instructed otherwise.

The most serious risks include cholinergic crisis, which can cause severe respiratory muscle weakness, bradycardia, bronchospasm, and seizures. Prompt medical attention is required if symptoms such as difficulty breathing, extreme muscle weakness, or fainting occur.

Mestinon should be avoided in patients with known hypersensitivity to pyridostigmine or any excipients, in those with severe asthma or chronic obstructive pulmonary disease prone to bronchospasm, and in individuals with uncontrolled cardiac arrhythmias unless closely monitored by a physician.